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Introduction {#sec005}
============

The incidence of vertebral osteomyelitis has increased over recent years, likely due to longer life expectancies, higher prevalence of chronic disease, and more effective diagnostic techniques \[[@pone.0211888.ref001]--[@pone.0211888.ref004]\]. Furthermore, healthcare-associated infections, such as catheter-related and device-related bloodstream infections, also increase the risk of vertebral osteomyelitis \[[@pone.0211888.ref005],[@pone.0211888.ref006]\]. Empiric antibiotic therapy should be withheld until a microbiological diagnosis is confirmed, but it should be provided immediately to septic patients or those with neurologic compromise \[[@pone.0211888.ref007],[@pone.0211888.ref008]\]. In addition, patients with no microbiological diagnosis after appropriate diagnostic tests may require empiric antibiotic treatment. Some authors recommended a second percutaneous needle biopsy in these patients \[[@pone.0211888.ref008],[@pone.0211888.ref009]\]. An open biopsy may provide a higher microbiological yield than percutaneous needle biopsy \[[@pone.0211888.ref010]--[@pone.0211888.ref012]\]. Despite these efforts, the causative microorganisms are not identified in as many as 17--50% of cases \[[@pone.0211888.ref002],[@pone.0211888.ref004],[@pone.0211888.ref012]--[@pone.0211888.ref015]\]. Although the reason for this is uncertain, biopsy culture yield may be reduced by prior antibiotic use \[[@pone.0211888.ref013],[@pone.0211888.ref016]\], non-purulent samples (i.e., bone tissue compared with soft tissue abscess) \[[@pone.0211888.ref017]\], and small volume of aspiration samples \[[@pone.0211888.ref018]\].

The selection of an empiric antimicrobial regimen for vertebral osteomyelitis should be based on consideration of the most likely causative pathogens and knowledge of local susceptibility patterns. Fluoroquinolone-based oral combinations were frequently used or recommended for empiric treatment for culture-negative vertebral osteomyelitis \[[@pone.0211888.ref001],[@pone.0211888.ref002],[@pone.0211888.ref019],[@pone.0211888.ref020]\]. However, these studies were conducted in an epidemiologic setting featuring a low prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) \[[@pone.0211888.ref002],[@pone.0211888.ref019],[@pone.0211888.ref020]\], and the appropriateness of these regimens in high-MRSA-prevalence settings was not evaluated. The aim of this study was to evaluate the appropriateness of empiric antibiotic regimens suggested for treatment of hematogenous vertebral osteomyelitis (HVO) using the susceptibility data of pathogens isolated from cases of culture-proven HVO. We hypothesized that patients with healthcare-associated HVO would more frequently be infected with antibiotic-resistant organisms than those with community-acquired HVO. Therefore, the appropriateness of empiric antibiotic regimens was also assessed according to the risk of healthcare-associated infection.

Methods {#sec006}
=======

Study design and setting {#sec007}
------------------------

This observational cohort study was undertaken at five tertiary-care hospitals in the Republic of Korea, and included all adult patients diagnosed with HVO from January 2005 to December 2012. The study was conducted using the format recommended by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines \[[@pone.0211888.ref021]\]. This study was approved by the Institutional Review Board of Gyeongsang National University Changwon Hospital (GNUCH 2018-05-010). Informed consent was waived because of the retrospective nature of the study.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Adult patients (≥18 years of age) who presented with microbiologically proven HVO were included in this study. The diagnosis of HVO was established using previously published criteria \[[@pone.0211888.ref022],[@pone.0211888.ref023]\], which included compatible clinical features, radiological evidence of vertebral osteomyelitis, and microbiologic demonstration of bacterial pathogens, either from the site of infection itself (*e*.*g*., abscess, intervertebral disc, or vertebral bone) or in the blood. Possible skin contaminants, such as coagulase-negative staphylococci (CoNS) and *Propionibacterium acnes*, were considered as true pathogens if they were isolated from ≥2 surgical, percutaneous biopsy, or blood cultures. Cases were excluded if there was a nonhematogenous source of vertebral infection, which included (1) penetrating trauma, (2) previously placed hardware, (3) laminectomy within 1 year prior to the vertebral osteomyelitis diagnosis, or (4) the presence of a stage 3--4 decubitus ulcer at the time of diagnosis \[[@pone.0211888.ref022],[@pone.0211888.ref023]\]. Cases of tuberculous, brucellar, and fungal vertebral osteomyelitis were excluded using mycobacterial culture, nucleic acid amplification test for *Mycobacterium tuberculosis*, histopathologic examination, *Brucella* serology, and fungal culture.

Data collection {#sec009}
---------------

Medical records were reviewed retrospectively for demographic information, underlying illness/conditions, presumed source of infection, diagnostic work-up, clinical presentation, and laboratory and radiological data. The present study builds on our previous work on the optimal duration of antibiotic therapy in patients with HVO \[[@pone.0211888.ref023]\].

Microbiological analysis {#sec010}
------------------------

The species and susceptibility profiles of all isolates were confirmed using either the Vitek2 (bioMérieux, Marcy-l\'Etoile, France) or Microscan (Dade Behring Inc., Deerfield, IL) automated systems. The susceptibility of isolates pathogens to 15 antibiotics was assessed (amoxicillin, amoxicillin-clavulanate, ciprofloxacin, levofloxacin, clindamycin, rifampin, trimethoprim-sulfamethoxazole, fusidic acid, cefazolin, ceftriaxone, ceftazidime, cefepime, vancomycin, teicoplanin, and linezolid). Isolated strains were categorized by the Clinical Laboratory Standard Institute (CLSI) guidelines as susceptible, intermediate, or resistant to antimicrobial agents\[[@pone.0211888.ref024],[@pone.0211888.ref025]\]. Prior to 2010, susceptibility breakpoints for cefazolin, ceftriaxone, and ceftazidime were ≤8 mg/L for *Enterobacteriaceae* \[[@pone.0211888.ref024]\]. In 2010, CLSI reduced breakpoints to ≤2 mg/L for cefazolin, ≤1 mg/L for ceftriaxone, and ≤4 mg/L for ceftazidime \[[@pone.0211888.ref025]\]. Cefepime susceptibility breakpoint for *Enterobacteriaceae* was 8 mg/L during entire study period \[[@pone.0211888.ref025]\]. Given the risk of treatment failure for intermediate strains, strains classified "intermediate" were reclassified as resistant. If the susceptibility results for surgery, percutaneous biopsy, and blood cultures were different, overall susceptibility was classified resistant.

We evaluated the overall susceptibility of eight antibiotics, alone or in combination, for empiric treatment of HVO, which were used or recommended in previous literatures. They included three fluoroquinolone-based oral combinations (levofloxacin plus rifampin, levofloxacin plus clindamycin, ciprofloxacin plus amoxicillin-clavulanate) \[[@pone.0211888.ref001],[@pone.0211888.ref002],[@pone.0211888.ref019],[@pone.0211888.ref020]\], four vancomycin-based intravenous combinations (vancomycin plus ciprofloxacin, ceftriaxone, ceftazidime, and cefepime) \[[@pone.0211888.ref008],[@pone.0211888.ref026]\], and cefazolin monotherapy \[[@pone.0211888.ref014],[@pone.0211888.ref027]\]. For *Staphylococcus* species, overall susceptibility to fluoroquinolone-based combinations was classified as susceptible if the organisms were susceptible to both antimicrobial agents (except for clindamycin, which can be used as a monotherapy on *Staphylococcus* species) \[[@pone.0211888.ref008]\]. For all other species, strains were considered susceptible if they showed susceptibility to at least one of the antimicrobial agent combinations.

Definitions {#sec011}
-----------

HVO was classified as community-acquired or healthcare-associated HVO according to published criteria \[[@pone.0211888.ref005]\]. Healthcare-associated HVO was defined as (i) onset of symptoms after 1 month of hospitalization with no evidence of vertebral osteomyelitis at admission, (ii) hospital admission within 6 months before symptom onset, or (iii) ambulatory diagnostic or therapeutic manipulations within 6 months before symptom onset (long-term central venous catheter use, arteriovenous fistula for hemodialysis, invasive intravascular techniques, urological, gynecological or digestive procedures, and cutaneous manipulations). Cases that did not meet any of the above criteria were classified as community-acquired HVO \[[@pone.0211888.ref005]\].

Statistical analyses {#sec012}
--------------------

Categorical variables are expressed as numbers and percentages and were compared by χ2 or Fisher's exact test. Continuous variables are expressed as medians and interquartile ranges and were compared using Mann-Whitney *U* test. All statistical tests were two-tailed, and *P* ≤ 0.05 was considered to indicate statistical significance. All statistical analyses were performed using SPSS for Windows software (ver. 18.0; SPSS, Inc., Chicago, IL).

Results {#sec013}
=======

In total, 370 patients with microbiologically proven HVO were identified during the study period. Of the 370 cases, 12 were excluded due to incomplete medical records and 358 were included in the final analysis.

Patients' characteristics {#sec014}
-------------------------

The demographic and baseline characteristics of the patients are displayed in [Table 1](#pone.0211888.t001){ref-type="table"}. The median age of the cohort was 65 years, and 186 (52.0%) were males. The most common underlying condition was diabetes (29.3%), followed by liver cirrhosis (9.2%) and malignancy (8.7%). According to the predefined criteria, 225 (62.8%) cases were community-acquired HVO and 133 (37.2%) were healthcare-associated HVO.

10.1371/journal.pone.0211888.t001

###### Demographic and baseline characteristics of 358 patients with hematogenous vertebral osteomyelitis.

![](pone.0211888.t001){#pone.0211888.t001g}

  -----------------------------------------------------------------------------------------------------------
  Variable                                                                                   All patients\
                                                                                             (*n* = 358)
  ------------------------------------------------------------------------------------------ ----------------
  Age, median years (IQR)                                                                    65 (58--72)

  Male sex                                                                                   186 (52.0)

  Underlying illness/conditions                                                              

  Diabetes mellitus                                                                          105 (29.3)

  Liver cirrhosis                                                                            33 (9.2)

  Malignancy                                                                                 31 (8.7)

  Immunosuppression                                                                          20 (5.6)

  End-stage renal disease                                                                    15 (4.2)

  Rheumatic disease                                                                          12 (3.4)

  Healthcare-associated HVO                                                                  133 (37.2)

  Presumed source of infection                                                               

  Urinary tract                                                                              35 (9.7)

  Skin and subcutaneous tissues                                                              30 (8.4)

  Intraabdominal                                                                             26 (7.3)

  Infected vascular access                                                                   25 (7.0)

  Endocarditis                                                                               19 (5.3)

  Unknown                                                                                    223 (62.3)

  Clinical data                                                                              

  Time to diagnosis, median days (IQR)                                                       22 (8--40)

  Back pain                                                                                  319 (89.1)

  Body temperature \> 38°C                                                                   190 (53.1)

  Neurologic deficit at diagnosis                                                            61 (17.0)

  Concurrent metastatic infection                                                            46 (12.8)

  Laboratory data                                                                            

  White blood cell count, ×10^9/^L, median (IQR)                                             114 (79--162)

  C-reactive protein, mg/dL, median (IQR)                                                    13 (6--22)

  Erythrocyte sedimentation rate, mm/h, median (IQR)[^a^](#t001fn003){ref-type="table-fn"}   76 (55--100)

  Positive blood cultures                                                                    265/339 (78.2)

  Radiologic data                                                                            

  Involvement of \> 2 vertebral bodies                                                       125 (34.9)

  Involvement of cervical spine                                                              31 (8.7)

  Involvement of thoracic spine                                                              85 (23.7)

  Involvement of lumbosacral spine                                                           283 (79.1)

  Epidural involvement[^b^](#t001fn004){ref-type="table-fn"}                                 194 (54.2)

  Paravertebral involvement[^b^](#t001fn004){ref-type="table-fn"}                            192 (53.6)

  Psoas involvement[^b^](#t001fn004){ref-type="table-fn"}                                    126 (35.2)
  -----------------------------------------------------------------------------------------------------------

Data are no. (%) of patients, unless otherwise indicated.

Abbreviations: HVO, hematogenous vertebral osteomyelitis; IQR, interquartile range

^a^ Measured in 287 patients.

^b^ Either abscess or phlegmon.

Microbiological findings {#sec015}
------------------------

Of the 358 cases with microbiologically proven HVO, 93 (26.0%) were identified by diagnostic biopsy, 173 (48.3%) by blood cultures, and 92 (25.7%) by both. The most frequently isolated organisms were methicillin-susceptible *Staphylococcus aureus* (MSSA) (33.5%), follow by MRSA \[24.9%\]), *Enterobacteriaceae* (19.3%), and *Streptococcus* species (11.7%; [Table 2](#pone.0211888.t002){ref-type="table"}). Of 42 *Streptococcus* species, viridans group streptococci were the most frequently isolated organisms (*n* = 21), followed by *Streptococcus agalactiae* (*n* = 15), *S*. *pneumoniae* (*n* = 4), and other streptococci (*n* = 2). CoNS, *Enterococcus* species, anaerobes, *Pseudomonas* species, and polymicrobial organisms accounted for 2.8%, 2.8%, 1.4%, 1.4%, and 0.8%, respectively.

10.1371/journal.pone.0211888.t002

###### Antibiotic susceptibility testing results for 358 isolated microorganisms.

![](pone.0211888.t002){#pone.0211888.t002g}

  Organism                                                 Percentage of isolates susceptible to                                                                                            
  -------------------------------------------------------- --------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ----- ----- -----
  Methicillin-susceptible *S*. *aureus* (*n* = 120)        14.3                                    0      94.2   95.8   88.3   97.5   100    74.1   100    NA     NA     NA     100   100   100
  Methicillin-resistant *S*. *aureus* (*n* = 89)           0                                       100    53.9   56.2   41.6   77.5   92.1   81.2   0      NA     NA     NA     100   100   100
  Coagulase-negative staphylococci (*n* = 10)              30.0                                    50.0   70.0   70.0   70.0   80.0   80.0   NA     50.0   NA     NA     NA     100   100   100
  *Streptococcus* species (*n* = 42)                       90.5                                    95.2   NA     90.5   76.2   NA     NA     NA     100b   95.2   NA     NA     100   100   100
  *Enterococcus* species (*n* = 10)                        80.0                                    90.0   NA     NA     NA     NA     NA     NA     0      NA     NA     NA     100   100   100
  *Enterobacteriaceae* (*n* = 69)                          27.5                                    76.8   75.4   75.4   NA     NA     84.1   NA     82.6   91.3   91.3   91.3   NA    NA    NA
  *Pseudomonas aeruginosa* (*n* = 5)                       NA                                      0      100    100    NA     NA     0      NA     0      0      100    100    NA    NA    NA
  Other (*n* = 13)[^c^](#t002fn004){ref-type="table-fn"}   NA                                      46.2   30.8   30.8   NA     NA     NA     NA     0      15.4   23.1   23.1   NA    NA    NA

Abbreviations: AMX, amoxicillin; AMX-CL, amoxicillin-clavulanate; CFP, cefepime; CAZ, ceftazidime; CFZ, cefazolin; CIP, ciprofloxacin; CLM, clindamycin; CTR, ceftriaxone; FA, fusidic acid; LEVO, levofloxacin; LZD, linezolid; MRSA, methicillin-resistant *S*. *aureus*; MSSA, methicillin-susceptible *S*. *aureus*; RIF, rifampin; TEC, teicoplanin; TMP-SMX; trimethoprim-sulfamethoxazole; VANC, vancomycin.

^a^ Susceptibility data for fusidic acid against methicillin-susceptible *S*. *aureus* and methicillin-resistant *S*. *aureus* isolates were available in 112 and 85 cases, respectively.

^b^ Excluding 25 streptococcal isolates without susceptibility data (21 viridans group streptococci and 4 *S*. *pneumoniae*); the remaining 17 *Streptococcus* isolates were susceptible to cefazolin.

^c^ Included *Bacteroides fragilis* (*n* = 2), *Bacteroides ureolyticus* (*n* = 1), *Prevotella melaninogenica* (*n* = 1), *Prevotella oralis* (*n* = 1), *Micrococcus* species (*n* = 1), *Pseudomonas putida* (*n* = 1), *Burkholderia cepacia* (*n* = 1), *Aggregatibacter aphrophilus* (*n* = 1), *Chryseobacterium meningosepticum* (*n* = 1), *Enterococcus faecium*/viridans group streptococci (*n* = 1), *Klebsiella pneumoniae*/*Enterobacter aerogenes* (*n* = 1), and methicillin-susceptible *S*. *aureus*/methicillin-resistant *Staphylococcus schleiferi* (*n* = 1).

There were some differences in the proportions of pathogens between community-acquired HVO and healthcare-associated HVO. MRSA was more frequent in healthcare-associated HVO than in community-acquired HVO (43.6% vs. 13.8%; *P* \< 0.001), but MSSA was more frequent in community-acquired HVO than in healthcare-associated HVO (44.0% vs. 13.8%; *P* \< 0.001). *Streptococcus* species were more frequent in community-acquired cases than in healthcare-associated cases (16.0% vs. 4.5%; *P* = 0.001). This trend was consistent across different *Streptococcus* species: viridans group streptococci (8.0% vs. 2.3%; *P* = 0.03), *Streptococcus agalactiae* (5.3% vs. 2.2%; *P* = 0.16) and *Streptococcus pneumoniae* (1.8% vs. 0%; *P* = 0.30).

Antimicrobial susceptibility profiles of isolated organisms {#sec016}
-----------------------------------------------------------

The antimicrobial susceptibility testing results of isolated microorganisms are shown in [Table 2](#pone.0211888.t002){ref-type="table"}. About 95% of MSSA isolates were susceptible to fluoroquinolones, compared to only half of the MRSA isolates. Of 69 *Enterobacteriaceae* isolates, 17 (24.6%) were resistant to ciprofloxacin, and 6 (8.7%) were extended-spectrum β-lactamase (ESBL) producers. All five *Pseudomonas aeruginosa* isolates were susceptible to ciprofloxacin. Of 42 *Streptococcus* species isolates, 40 (95.2%) were susceptible to amoxicillin-clavulanate and 38 (90.5%) were susceptible to levofloxacin. Of the 10 CoNS isolates, 5 (50%) were methicillin-resistant CoNS.

Relevance of empirical antibiotic regimens for HVO {#sec017}
--------------------------------------------------

The relevance of empiric antibiotic regimens for HVO is shown in [Table 3](#pone.0211888.t003){ref-type="table"}. Overall, 73.5% of isolated pathogens were susceptible to levofloxacin plus rifampicin, 71.2% to levofloxacin plus clindamycin, and 64.5% to amoxicillin-clavulanate plus ciprofloxacin. The susceptibility to these oral combinations was lower in cases of healthcare-associated HVO (52.6%, 49.6%, and 37.6%, respectively) than in cases of community-acquired HVO (85.8%, 84.0%, and 80.4%, respectively). Vancomycin combined with ciprofloxacin, ceftriaxone, ceftazidime, or cefepime was similarly appropriate (susceptibility rates 93.0%, 94.1%, 95.8%, and 95.8%, respectively). All antibiotic regimens gave similar results, irrespective patients' age and blood culture positivity.

10.1371/journal.pone.0211888.t003

###### Relevance of empiric antibiotic therapy based on the susceptibility results of organisms isolated from hematogenous vertebral osteomyelitis.

![](pone.0211888.t003){#pone.0211888.t003g}

  Organism                                                                  LEVO + RIF   LEVO + CLM   AMX-CL + CIP   CFZ[^a^](#t003fn004){ref-type="table-fn"}   VAN + CIP   VAN + CTR   VAN + CAZ   VAN + FEP
  ------------------------------------------------------------------------- ------------ ------------ -------------- ------------------------------------------- ----------- ----------- ----------- -----------
  All cases (*n* = 358)                                                     73.5         71.2         66.5           61.6                                        93.0        94.1        95.8        95.8
  Microorganisms                                                                                                                                                                                     
      Methicillin-susceptible *S*. *aureus* (*n* = 120)                     93.3         88.3         94.2           100                                         100         100         100         100
      Methicillin-resistant *S*. *aureus* (*n* = 89)                        50.6         41.6         0              0                                           100         100         100         100
      Coagulase-negative staphylococci (*n* = 10)                           70.0         70.0         50.0           50.0                                        100         100         100         100
      *Streptococcus* species (*n* = 42)                                    90.5         97.6         100            100[^b^](#t003fn005){ref-type="table-fn"}   100         100         100         100
      *Enterococcus* species (*n* = 10)                                     0            0            90.0           0                                           100         100         100         100
      *Enterobacteriaceae* (*n* = 69)                                       75.4         75.4         78.3           82.6                                        75.4        91.3        91.3        91.3
      *Pseudomonas aeruginosa* (*n* = 5)                                    100          100          0              60.0                                        100         0           100         100
      Other (*n* = 13)                                                      30.8         53.8         61.5           23.1                                        38.5        23.1        30.8        30.8
  Onset of infection                                                                                                                                                                                 
      Community-acquired (*n* = 225)                                        85.8         84.0         80.4           78.3                                        94.2        96.9        97.3        97.3
      Healthcare-associated (*n* = 133)                                     52.6         49.6         37.6           35.4                                        91.0        89.5        93.2        93.2
  Age                                                                                                                                                                                                
      \<65 years (*n* = 165)                                                77.6         72.7         69.1           67.8                                        93.3        93.9        95.8        95.8
      ≥65 years (*n* = 193)                                                 69.9         69.9         60.6           56.5                                        92.7        94.3        95.9        95.9
  Blood culture                                                                                                                                                                                      
      Non-bacteremic HVO (*n* = 93)[^c^](#t003fn006){ref-type="table-fn"}   77.4         79.6         66.7           61.4                                        91.7        86.0        92.5        92.5
      Bacteremic HVO (*n* = 265)                                            72.1         68.3         63.8           61.6                                        92.8        97.0        97.0        97.0

Data are no. (%) of isolates, unless otherwise indicated.

Abbreviations: AMX-CL, amoxicillin-clavulanate; FEP, cefepime; CAZ, ceftazidime; CIP

ciprofloxacin; CFZ, cefazolin; CLM, clindamycin; CTR, ceftriaxone; HVO, hematogenous vertebral osteomyelitis; LEVO, levofloxacin; RIF, rifampin; VAN, vancomycin.

^a^ After excluding 25 streptococcal isolates without susceptibility data (21 viridans group streptococci and 4 *S*. *pneumoniae*), 333 isolates were included in analysis.

^b^ After excluding 25 streptococcal isolates without susceptibility data (21 viridans group streptococci and 4 *S*. *pneumoniae*), the remaining 17 *Streptococcus* isolates were susceptible to cefazolin.

^c^ Included patients with negative blood culture results (*n* = 74) and those from whom blood cultures were not obtained (*n* = 19).

Discussion {#sec018}
==========

We evaluated the susceptibility profiles of microorganisms causing HVO and assessed the appropriateness of several empiric antibiotic regimens for HVO. Our data showed that oral antibiotic combinations may be suboptimal for empiric treatment of HVO, especially in cases of healthcare-associated HVO. Vancomycin combined with fluoroquinolones or broad-spectrum cephalosporin may be appropriate for most cases of HVO.

In this study, the most frequently isolated organism was *S*. *aureus*, with 43% being MRSA. In recent years, the prevalence of MRSA among *S*. *aureus* vertebral osteomyelitis has been reported to be 40--57% \[[@pone.0211888.ref022],[@pone.0211888.ref026],[@pone.0211888.ref028],[@pone.0211888.ref029]\]. The resistance rate of *Enterobacteriaceae* isolates to ciprofloxacin was 26% in this study, compared to 31% and 38% in two recent studies conducted in South Korea and France, respectively \[[@pone.0211888.ref030],[@pone.0211888.ref031]\]. Vertebral osteomyelitis caused by antibiotic-resistant organisms may have a higher risk of treatment failure \[[@pone.0211888.ref028],[@pone.0211888.ref032],[@pone.0211888.ref033]\]. Indeed, patients with MRSA vertebral osteomyelitis reportedly have a 4--5-fold higher risk of recurrence than those with MSSA vertebral osteomyelitis \[[@pone.0211888.ref028],[@pone.0211888.ref032]\]. In a study of patients with gram-negative bacterial HVO treated with 4--8 weeks of antibiotic treatment, 50% (4/8) of patients infected with fluoroquinolone-resistant strains experienced recurrence, but 16.7% (1/6) of patients infected with fluoroquinolone-resistant strains experienced recurrence \[[@pone.0211888.ref033]\]. Thus, the increasing incidence of antibiotic resistance in causative pathogens of vertebral osteomyelitis should be considered when selecting an empiric antibiotic regimen for HVO.

In seriously ill patients with suspected vertebral osteomyelitis, empiric antibiotic should be initiated in conjunction with an attempt at establishing a microbiologic diagnosis. We found that most of the isolated pathogens were susceptible to vancomycin plus ciprofloxacin or broad-spectrum cephalosporin. Although ESBL-producing *Enterobacteriaceae* accounted for 8.7% of the *Enterobacteriaceae* isolates, it accounted for only 1.7% of all causative organisms. The prevalence of anaerobes was 1.4% in this work, and up to 4% in two recent studies \[[@pone.0211888.ref002],[@pone.0211888.ref034]\]. It may be underestimated because the successful isolation of anaerobic organisms largely depends on the quality of culture samples, mode of transport, and condition of culture. Despite this, antibiotic coverage of anaerobes (with carbapenems or metronidazole) may be not required initially, taking into account the rarity of these organisms and the risk of antibiotic overuse. It should be limited to patients who show no clinical improvement after empiric treatment and negative results of repeated biopsies. Patients with renal dysfunction or critical illness are at risk of developing vancomycin-induced nephrotoxicity, particularly when prolonged treatment is required. Alternative agents to vancomycin include teicoplanin, linezolid, daptomycin, and dalbavancin. Bone penetration was superior with teicoplanin but high dose therapy was required to treat staphylococcal osteomyelitis. Linezolid is recommended as an option for MRSA osteomyelitis, although the increasing risk of bone marrow suppression with prolonged courses of linezolid is a concern \[[@pone.0211888.ref008]\]. Recently, a retrospective analysis of 61 cases of MRSA vertebral osteomyelitis showed that patients treated with daptomycin had a higher cure rate than those treated with vancomycin (97% \[30/31\] vs 70% \[21/30\]; *P* = .006) \[[@pone.0211888.ref035]\].

In patients with no microbiological confirmation after routine diagnostic tests, several considerations should be made before starting empiric antibiotic therapy. First, *M*. *tuberculosis* and *Brucella* species should be excluded by appropriate diagnostic tests. Second, Concomitant infective endocarditis should be excluded in patients with underlying cardiac diseases. Bacteremic vertebral osteomyelitis caused by *Streptococcus* and *Enterococcus* species was frequently associated with infective endocarditis \[[@pone.0211888.ref036]--[@pone.0211888.ref039]\]. Third, there are some issues for use of fluoroquinolone-based regimens for treatment of staphylococcal vertebral osteomyelitis, although they have been frequently used not only in microbiologically proven cases \[[@pone.0211888.ref034],[@pone.0211888.ref040]\], but also in cases of no microbiologic diagnosis \[[@pone.0211888.ref002],[@pone.0211888.ref019],[@pone.0211888.ref020]\]. Two previous studies showed that empiric treatment for vertebral osteomyelitis with levofloxacin plus rifampin had overall response rates of 78% (14/18) \[[@pone.0211888.ref002]\] and 84% (37/44) \[[@pone.0211888.ref019]\]. In another study, empiric treatment with ciprofloxacin plus amoxicillin-clavulanate had an overall response rate of 82% (18/22) \[[@pone.0211888.ref020]\]. Most of these studies were conducted in an epidemiologic setting featuring a low prevalence of MRSA \[[@pone.0211888.ref002],[@pone.0211888.ref019],[@pone.0211888.ref020]\]. In the current study, 64.5--73.5% of causative organisms were susceptible to fluoroquinolone conjunction with rifampin, clindamycin, or amoxicillin-clavulanate. The substantial rates of non-susceptibility to these regimens may be due to the high prevalence of MRSA (25%). Almost half of our MRSA isolates were resistant to fluoroquinolones, and the resistance rates to their companion drugs, such as rifampin and clindamycin, were high (22% and 58%, respectively). Fluoroquinolone plus rifampin are the most extensively studied combination for MSSA osteoarticular infections, but there is limited clinical experience of MRSA osteoarticular infections with such a combination \[[@pone.0211888.ref041],[@pone.0211888.ref042]\]. Clinical guidelines recommend fluoroquinolone plus rifampin and clindamycin as acceptable alternatives for staphylococcal osteomyelitis, but they do not recommend fluoroquinolone monotherapy and oral β-lactams such amoxicillin-clavulanate and first-generation cephalosporin \[[@pone.0211888.ref008],[@pone.0211888.ref043]\]. Fourth, in areas of high incidence of fluoroquinolone-resistant *Enterobacteriaceae*, fluoroquinolones should not be used especially if the patient has a previous history of healthcare-associated urinary tract infection or urinary tract infection due to fluoroquinolone-resistant *Enterobacteriaceae* \[[@pone.0211888.ref044],[@pone.0211888.ref045]\]. Recently, Desoutter *et al*. reported the susceptibility patterns of microorganisms isolated from 101 cases of non-bacteremic vertebral osteomyelitis by percutaneous needle biopsy \[[@pone.0211888.ref030]\]. The isolated pathogens were susceptible to fluoroquinolone-based regimens (conjunction with rifampin, clindamycin, and amoxicillin-clavulanate) in 58--77% of cases \[[@pone.0211888.ref030]\]. In that study, in contrast to our study, MRSA was responsible for 5% of cases of vertebral osteomyelitis, but 39% of *Enterobacteriaceae* isolates was resistant to fluoroquinolone \[[@pone.0211888.ref030]\]. Finally, empiric antibiotic should be based on the host and the epidemiologic risk, as well as the local historical in vitro susceptibility data. To minimize the risk of microbiological failure due to resistant organisms, we reassessed the suitability of empiric regimens in community-acquired and healthcare-associated cases. These analyses indicated that overall resistance rate of isolated organisms to fluoroquinolone-based regimens was high (47--62%) in healthcare-associated cases and still substantial (14--20%) in community-acquired cases. Aguilar-Company reported that elderly patients with vertebral osteomyelitis had higher rates of healthcare-associated than younger patients \[[@pone.0211888.ref046]\], but we found no difference in overall susceptibility to empiric antibiotic regimens between both groups. Taken together, we suggest that fluoroquinolone-based oral combinations may be not appropriate due to frequent resistance to these agents, especially in cases of healthcare-associated HVO.

For culture-negative vertebral osteomyelitis, some authors suggest a first-generation cephalosporin for community-acquired cases and vancomycin-containing regimens for post-surgical cases, and have reported favorable outcomes with this approach \[[@pone.0211888.ref014],[@pone.0211888.ref027]\]. A first-generation cephalosporin is an acceptable alternative in patients unable to tolerate anti-staphylococcal penicillin \[[@pone.0211888.ref047]\], but clinical experience with this agent for streptococcal and gram-negative bacterial osteomyelitis is limited. In addition, first-generation cephalosporin show varying activity against α-hemolytic streptococci, unlike β-hemolytic streptococci \[[@pone.0211888.ref048]\], and susceptibility testing of this agent against α-hemolytic streptococci is not recommended \[[@pone.0211888.ref024]\]. Even after excluding 25 cases of α-hemolytic streptococci without susceptibility data (viridans group streptococci \[n = 21\] and *S*. *pneumoniae* \[n = 4\]), cefazolin was appropriate in only 62% of cases. More data on the efficacy of first-generation cephalosporin is required before they can be widely used for culture-negative vertebral osteomyelitis.

Our study had several limitations. First, some cases lacked antibiotic susceptibility test results and so exclusion of these cases may have introduced bias. Second, we assessed the appropriateness of empiric antibiotic regimens for culture-negative HVO based on the data of organisms isolated from microbiologically proven cases. The bacterial etiology in culture-negative vertebral may differ according to diagnostic criteria and tests. Culture-negative vertebral osteomyelitis is less likely to be caused by *Staphylococcus* species, but it may be more likely to be caused by *Streptococcus* species \[[@pone.0211888.ref002],[@pone.0211888.ref038]\]. Thus, our data may be more useful for selecting empiric antibiotics in seriously ill patients who require immediate antibiotic treatment than in those with no microbiological diagnosis. Despite this, we believe that our suggested regimens (vancomycin plus broad-spectrum cephalosporin or fluoroquinolone) may be also reasonable for the latter patients, when considering the risks of inappropriate antibiotic therapy and antibiotic overuse. Finally, this study included only patients with HVO, and so our findings should not be extrapolated to cases of post-surgical vertebral osteomyelitis, in which CoNS and antibiotic-resistant organisms may be more common.

In summary, in a setting in which MRSA is a frequent causative organism of HVO, cautious selection of empiric antibiotics is required. Oral antibiotic combinations may be suboptimal due to frequent resistance to these agents, especially in healthcare-associated cases. Vancomycin combined with fluoroquinolone or a broad-spectrum cephalosporin may be appropriate in most cases of HVO. It should be noted that our evaluation of the suitability of the empiric regimens for HVO was just based on overall susceptibility of isolated pathogens for microbiologically proven cases. Therefore, further studies are required to clarify the clinical impact of empiric regimens suggested here on patients' outcomes.
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